Rachel Capone, MSHS, is a regulatory affairs manager, Syner-G BioPharma Group.
Unlocking the Benefits of FDA’s Orphan Drug Designation
How Climate-Driven Disasters Could Reshape Health Care Quality Measures
Enhancing Diversity, Addressing Racial Disparities in Psoriatic Arthritis Research
Camden Coalition’s Complex Care Education Extends to Various Sectors
Bimekizumab, Brodalumab Safe, Effective Up to 36 Weeks for Psoriasis